Inclisiran Sodium Patent Expiration
Inclisiran Sodium is Used for reducing cholesterol levels in adults with certain genetic disorders or cardiovascular diseases by inhibiting the PCSK9 gene expression in combination with diet and statin therapy. It was first introduced by Novartis Pharmaceuticals Corp
Inclisiran Sodium Patents
Given below is the list of patents protecting Inclisiran Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Leqvio | US10851377 | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder | Aug 25, 2036 | Novartis |
| Leqvio | US10125369 | PCSK9 iRNA compositions and methods of use thereof | Aug 18, 2034 | Novartis |
| Leqvio | US12460206 | Pcsk9 Irna Compositions And Methods Of Use Thereof | Aug 18, 2034 | Novartis |
| Leqvio | US8106022 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 12, 2029 | Novartis |
| Leqvio | US10806791 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 04, 2028 | Novartis |
| Leqvio | US8828956 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 04, 2028 | Novartis |
| Leqvio | US9370582 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 04, 2028 | Novartis |
| Leqvio | US10131907 | Glycoconjugates of RNA interference agents | Aug 24, 2028 | Novartis |
| Leqvio | US8222222 | Compositions and methods for inhibiting expression of the PCSK9 gene | Dec 29, 2027 | Novartis |
| Leqvio | US8809292 | Compositions and methods for inhibiting expression of the PCSK9 gene | May 10, 2027 | Novartis |
| Leqvio | US11530408 | Therapeutic compositions |
May 18, 2024
(Expired) | Novartis |
| Leqvio | US10273477 | Therapeutic compositions |
Mar 08, 2024
(Expired) | Novartis |
| Leqvio | US10669544 | Therapeutic compositions |
Mar 08, 2024
(Expired) | Novartis |
| Leqvio | US9708615 | Therapeutic compositions |
Mar 08, 2024
(Expired) | Novartis |
| Leqvio | US9708610 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan 01, 2024
(Expired) | Novartis |
| Leqvio | US10266825 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov 04, 2023
(Expired) | Novartis |
| Leqvio | US11078485 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov 04, 2023
(Expired) | Novartis |
| Leqvio | US8232383 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
Feb 20, 2023
(Expired) | Novartis |
| Leqvio | US10590418 | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
Jul 19, 2022
(Expired) | Novartis |
| Leqvio | US8546143 | Compositions and methods for inhibiting expression of a target gene |
Apr 23, 2022
(Expired) | Novartis |
| Leqvio | US9074213 | Compositions and methods for inhibiting expression of a target gene |
Mar 09, 2022
(Expired) | Novartis |
Inclisiran Sodium's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Inclisiran Sodium:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
